Analysis of clinical outcomes for ovarian cancer with minimal residual disease, highlighting therapeutic targets for treatment.
Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.
No takes yet. Share an insight, caveat, or question.
Knisely et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: